Silver Valley Pharmaceutical Co. Ltd.

Primary objective: To compare the pharmacokinetic characteristics of single fasting intramuscular injection in healthy adult participants in China using salmon calcitonin injection (specification: 1 mL: 100 IU) developed by Yingu Pharmaceutical Co., Ltd. as the test preparation (T) and salmon calcitonin injection (trade name: Miacalcic®; specification: 1 mL: 100 IU) certified by Future Health Pharma GmbH as the reference preparation (R), and to investigate the bioequivalence of the two preparations in humans. Secondary objective: To observe the safety and immunogenicity of the test preparation and reference preparation (trade name: Miacalcic®) of salmon calcitonin injection in healthy participants.

To observe the pharmacokinetic and pharmacodynamic characteristics of a single dose of bencyclidine bromide inhalation aerosol in patients with chronic obstructive pulmonary disease (COPD) and provide a basis for the formulation of a dosing regimen for Phase II clinical trials

To verify the efficacy and safety of bencyclidine nasal spray at a dose of 180 μg/time (90 μg/spray, 1 spray in each nostril each time), 4 times a day, in the treatment of runny nose, nasal congestion, nasal itching and sneezing symptoms caused by colds.